Screener
Kiniksa Pharmaceuticals International, plc KNSA Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Comprehensive Income (Loss), Net of Tax, Attributable to Parent at other companies
Other financials
Where this comes from
Reported directly by Kiniksa Pharmaceuticals International, plc in its filing.
Tagged under the XBRL concept us-gaap:ComprehensiveIncomeNetOfTax.
The source filing: Kiniksa Pharmaceuticals International, plc’s 10-Q, filed July 28, 2026.
- Filed
- Jul 28, 2026, 4:17 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-087545
| Line item | Three Months Ended / June 30, 2026 | Three Months Ended / June 30, 2025 | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|---|---|
| Weighted average ordinary shares outstanding—basic | 77,577,675 | 73,438,530 | 77,050,036 | 73,041,920 |
| Weighted average ordinary shares outstanding—diluted | 83,398,051 | 77,942,082 | 82,902,904 | 76,984,393 |
| Comprehensive income | ||||
| Net income | $25,432 | $17,832 | $48,024 | $26,371 |
| Other comprehensive income (loss) | ||||
| Unrealized gain (loss) on short-term investments and currency translation adjustments, net of tax | (715) | 112 | (1,355) | 110 |
| Total other comprehensive income (loss) | (715) | 112 | (1,355) | 110 |
| Total comprehensive income | $24,717 | $17,944 | $46,669 | $26,481 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Kiniksa Pharmaceuticals International, plc's comprehensive income (loss), net of tax, attributable to parent?
- Kiniksa Pharmaceuticals International, plc (KNSA) reported comprehensive income (loss), net of tax, attributable to parent of $24.72M in Q2 2026.
- How has Kiniksa Pharmaceuticals International, plc's comprehensive income (loss), net of tax, attributable to parent changed year-over-year?
- Kiniksa Pharmaceuticals International, plc's comprehensive income (loss), net of tax, attributable to parent increased by 37.7% year-over-year, from $17.94M to $24.72M.
- What is the long-term trend for Kiniksa Pharmaceuticals International, plc's comprehensive income (loss), net of tax, attributable to parent?
- Over 4 years (2021 to 2025), Kiniksa Pharmaceuticals International, plc's comprehensive income (loss), net of tax, attributable to parent has grown at a -21.8% compound annual growth rate (CAGR), from -$157.96M to $59.14M.
- What does comprehensive income (loss), net of tax, attributable to parent mean?
- Represents the total change in equity from non-owner sources, encompassing both net income and other comprehensive income items like unrealized gains or losses. It provides a broader measure of financial performance than net income alone by capturing all recognized economic gains and losses. This metric is essential for evaluating the total economic impact of all financial activities on shareholder value.
Ask your AI about Kiniksa Pharmaceuticals International, plc's comprehensive income (loss), net of tax, attributable to parent.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude